Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Celldex Therapeutics, Inc.CLDX · Entity 4208 | SVP & GENERAL COUNSEL | June 25, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Celldex Therapeutics, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.09 · Expires 2036-06-25 | Direct | 93,000 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 93,000 · Balance 93,000 F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
F2: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 29, 2026 20:21 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 93,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001838114-26-000002 · form4-06292026_080612.xml · derivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,000 Underlying: Common Stock · 93,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| December 04, 2025 Filed Dec 8, 2025 21:20 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | SaleCommon Stock | 4,166 | $29.10 | $121,209.77 |
DisclosureSEC source: 0001838114-25-000007 · form4-12082025_091231.xml · nonDerivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,796 Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 20:07 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | SaleCommon Stock | 430 | $25.42 | $10,928.45 |
DisclosureSEC source: 0001415889-25-022069 · form4-08152025_080825.xml · nonDerivative · entry 2 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,962 Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 20:07 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | SaleCommon Stock | 341 | $23.95 | $8,167.46 |
DisclosureSEC source: 0001415889-25-022069 · form4-08152025_080825.xml · nonDerivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,392 F1 · balance_after: Includes 269 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:18 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016244 · form4-06092025_080659.xml · derivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:19 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017190 · form4-06172024_080643.xml · derivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2025 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:05 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 9,540 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001415889-24-015950 · form4-06072024_080609.xml · derivative · entry 2 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,454 Underlying: Common Stock · 9,540 shares Expires 2030-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:05 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionCommon Stock | 9,540 | $10.38 | $99,025.20 |
DisclosureSEC source: 0001415889-24-015950 · form4-06072024_080609.xml · nonDerivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:04 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 8,006 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001415889-24-015542 · form4-06052024_080652.xml · derivative · entry 3 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,994 Underlying: Common Stock · 8,006 shares Expires 2030-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:04 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | SaleCommon Stock | 8,006 | $33.60 | $269,002.40 |
DisclosureSEC source: 0001415889-24-015542 · form4-06052024_080652.xml · nonDerivative · entry 2 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,924 Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:04 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionCommon Stock | 8,006 | $10.38 | $83,102.28 |
DisclosureSEC source: 0001415889-24-015542 · form4-06052024_080652.xml · nonDerivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,930 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:05 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001415889-24-003891 · form4-02152024_090240.xml · derivative · entry 4 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2029-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: As of June 19, 2023, the option is fully vested. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:05 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 4,166 | $0.00 Strike: $9.02 | $0.00 |
DisclosureSEC source: 0001415889-24-003891 · form4-02152024_090240.xml · derivative · entry 3 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,166 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 62,500 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. F1 · shares: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 62,500 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. F3 · derivative.exercise_date: As of June 13, 2022, the option is fully vested. F1 · derivative.underlying_shares: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 62,500 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:05 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionCommon Stock | 20,000 | $2.78 | $55,600.00 |
DisclosureSEC source: 0001415889-24-003891 · form4-02152024_090240.xml · nonDerivative · entry 2 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:05 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionCommon Stock | 4,166 | $9.02 | $37,562.74 |
DisclosureSEC source: 0001415889-24-003891 · form4-02152024_090240.xml · nonDerivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 62,500 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. F1 · price: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 62,500 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. F2 · balance_after: Includes 1,328 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:17 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 74,000 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010045 · form4-06202023_080605.xml · derivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,000 Underlying: Common Stock · 74,000 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:18 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 73,000 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001415889-22-006732 · form4-06172022_010617.xml · derivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,000 Underlying: Common Stock · 73,000 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 10:58 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | PurchaseCommon Stock | 430 | $46.28 | $19,900.40 |
DisclosureSEC source: 0001179110-21-008163 · edgar.xml · nonDerivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430 Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:29 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 73,000 | $0.00 Strike: $28.00 | $0.00 |
DisclosureSEC source: 0001179110-21-006912 · edgar.xml · derivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,000 Underlying: Common Stock · 73,000 shares Expires 2031-06-17 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 17, 2022 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.